Overactive Bladder - Pipeline Review, H1 2018

  • ID: 4529325
  • Drug Pipelines
  • 110 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Allergan Plc
  • Astellas Pharma Inc
  • Dong-A ST Co Ltd
  • Ipsen SA
  • Merck & Co Inc
  • Mylan NV
  • MORE
Overactive Bladder - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Overactive Bladder - Pipeline Review, H1 2018, provides an overview of the Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline landscape.

Overactive bladder is a problem with bladder-storage function that causes a sudden urge to urinate. The urge may be difficult to stop, and overactive bladder may lead to the involuntary loss of urine (incontinence). Symptoms include feel a sudden urge to urinate that's difficult to control, experience urge incontinence and awaken two or more times in the night to urinate. Treatment includes change in life style and medications that relax the bladder can be effective for relieving symptoms of overactive bladder and reducing episodes of urge incontinence.

Report Highlights:

This latest pipeline guide Overactive Bladder - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Overactive Bladder (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Overactive Bladder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 3, 5, 6, 6, 2, 10 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Overactive Bladder (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Overactive Bladder (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Overactive Bladder (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Overactive Bladder (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Overactive Bladder (Genito Urinary System And Sex Hormones)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Overactive Bladder (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Allergan Plc
  • Astellas Pharma Inc
  • Dong-A ST Co Ltd
  • Ipsen SA
  • Merck & Co Inc
  • Mylan NV
  • MORE
Introduction

Report Coverage

Overactive Bladder - Overview

Overactive Bladder - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Overactive Bladder - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Overactive Bladder - Companies Involved in Therapeutics Development

Allergan Plc

Asahi Kasei Pharma Corp

Astellas Pharma Inc

Dompe Farmaceutici SpA

Dong-A ST Co Ltd

FemmePharma Global Healthcare Inc

Hanmi Pharmaceuticals Co Ltd

Hydra Biosciences Inc

Ion Channel Innovations LLC

Ipsen SA

Juniper Pharmaceuticals Inc

Kissei Pharmaceutical Co Ltd

Kyorin Pharmaceutical Co Ltd

Lipella Pharmaceuticals Inc

Medy-Tox Inc

Merck & Co Inc

Mezzion Pharma Co Ltd

Mylan NV

Pfizer Inc

Recordati SpA

Taiho Pharmaceutical Co Ltd

Taris Biomedical LLC

TheraVida Inc

Toray Industries Inc

XuanZhu Pharma Co Ltd

Overactive Bladder - Drug Profiles

(mirabegron + solifenacin succinate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

abobotulinumtoxinA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AK-14 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DA-8010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DFL-23448 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fesoterodine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fesoterodine fumarate ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HC-067047 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ICE-3682 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KPR-2579 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mirabegron ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nivobotulinumtoxin A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OP-687 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oxybutynin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oxybutynin chloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Antagonize PACAP Receptor for Anxiety, Overactive Bladder and Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pVAX-hSlo - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REC-0438 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Block TRPV1 for Overactive Bladder - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize EP1 Receptor for Overactive Bladder - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize PTGER1 for Overactive Bladder - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solabegron - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solabegron MR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solifenacin succinate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solifenacin succinate DR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAC-302 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

THVD-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trospium chloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

udenafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vibegron - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XZP-5849 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Overactive Bladder - Dormant Projects

Overactive Bladder - Discontinued Products

Overactive Bladder - Product Development Milestones

Featured News & Press Releases

Mar 28, 2018: Urovant Sciences Initiates Phase 3 Clinical Program for Vibegron in Patients with Overactive Bladder

Mar 19, 2018: Velicept Therapeutics Initiates First of Two Phase 2b Dose-Ranging Studies of Solabegron in Patients with Overactive Bladder (OAB)

Mar 09, 2018: Astellas Received Approval for Solifenacin Oral Suspension for Pediatric Patients in Europe

Feb 28, 2018: Urovant Sciences Announces Upcoming Presentations of Data from Phase 2b Trial of Vibegron in Patients with Overactive Bladder

Jan 17, 2018: Outpost Medicine Announces Acceptance of Two Investigational New Drug Applications for OP-687 by U.S. FDA

Nov 06, 2017: UroGen Pharma Announces First Patient Enrolled in Allergan Phase 2 Clinical Trial of RTGel in Combination with BOTOX for the Treatment of Overactive Bladder

Sep 12, 2017: U.S. FDA Accepts for Review Astellas' Supplemental New Drug Application for mirabegron for Use in Combination with solifenacin succinate 5 mg for the Treatment of Overactive Bladder

Jul 19, 2017: Investigational New Drug Application for RTGel in Combination with BOTOX for the Treatment of Overactive Bladder Submitted to FDA by Allergan

Jun 30, 2017: Astellas Submits Supplemental New Drug Application for mirabegron for Use in Combination with solifenacin succinate 5 mg for the Treatment of Overactive Bladder

Oct 27, 2016: Velicept Therapeutics Names Clarence Young, M.D., Chief Medical Officer

Oct 07, 2016: Astellas Filed Lawsuit against Patent Infringement of Myrbetriq in the United States

Oct 05, 2016: Velicept Therapeutics Announces FDA Acceptance of IND Application of Novel, Once-Daily Formulation of Solabegron for the Treatment of Overactive Bladder

Sep 27, 2016: Allergan to Present New Data at the American Urogynecologic Society Annual Meeting in Denver

May 03, 2016: Allergan Presents New Data on OnabotulinumtoxinA at the American Urological Association Meeting in San Diego

Mar 21, 2016: Juniper Pharmaceuticals Affirms Development Pathway for Oxybutynin Intra-vaginal Ring for Overactive Bladder in Women

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Table 1: Number of Products under Development for Overactive Bladder, H1 2018

Table 2: Number of Products under Development by Companies, H1 2018

Table 3: Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Table 4: Number of Products under Development by Universities/Institutes, H1 2018

Table 5: Products under Development by Companies, H1 2018

Table 6: Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Table 7: Products under Development by Universities/Institutes, H1 2018

Table 8: Number of Products by Stage and Target, H1 2018

Table 9: Number of Products by Stage and Mechanism of Action, H1 2018

Table 10: Number of Products by Stage and Route of Administration, H1 2018

Table 11: Number of Products by Stage and Molecule Type, H1 2018

Table 12: Overactive Bladder - Pipeline by Allergan Plc, H1 2018

Table 13: Overactive Bladder - Pipeline by Asahi Kasei Pharma Corp, H1 2018

Table 14: Overactive Bladder - Pipeline by Astellas Pharma Inc, H1 2018

Table 15: Overactive Bladder - Pipeline by Dompe Farmaceutici SpA, H1 2018

Table 16: Overactive Bladder - Pipeline by Dong-A ST Co Ltd, H1 2018

Table 17: Overactive Bladder - Pipeline by FemmePharma Global Healthcare Inc, H1 2018

Table 18: Overactive Bladder - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018

Table 19: Overactive Bladder - Pipeline by Hydra Biosciences Inc, H1 2018

Table 20: Overactive Bladder - Pipeline by Ion Channel Innovations LLC, H1 2018

Table 21: Overactive Bladder - Pipeline by Ipsen SA, H1 2018

Table 22: Overactive Bladder - Pipeline by Juniper Pharmaceuticals Inc, H1 2018

Table 23: Overactive Bladder - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2018

Table 24: Overactive Bladder - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2018

Table 25: Overactive Bladder - Pipeline by Lipella Pharmaceuticals Inc, H1 2018

Table 26: Overactive Bladder - Pipeline by Medy-Tox Inc, H1 2018

Table 27: Overactive Bladder - Pipeline by Merck & Co Inc, H1 2018

Table 28: Overactive Bladder - Pipeline by Mezzion Pharma Co Ltd, H1 2018

Table 29: Overactive Bladder - Pipeline by Mylan NV, H1 2018

Table 30: Overactive Bladder - Pipeline by Pfizer Inc, H1 2018

Table 31: Overactive Bladder - Pipeline by Recordati SpA, H1 2018

Table 32: Overactive Bladder - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2018

Table 33: Overactive Bladder - Pipeline by Taris Biomedical LLC, H1 2018

Table 34: Overactive Bladder - Pipeline by TheraVida Inc, H1 2018

Table 35: Overactive Bladder - Pipeline by Toray Industries Inc, H1 2018

Table 36: Overactive Bladder - Pipeline by XuanZhu Pharma Co Ltd, H1 2018

Table 37: Overactive Bladder - Dormant Projects, H1 2018

Table 38: Overactive Bladder - Dormant Projects, H1 2018 (Contd..1), H1 2018

Table 39: Overactive Bladder - Dormant Projects, H1 2018 (Contd..2), H1 2018

Table 40: Overactive Bladder - Dormant Projects, H1 2018 (Contd..3), H1 2018

Table 41: Overactive Bladder - Discontinued Products, H1 2018

List of Figures

Figure 1: Number of Products under Development for Overactive Bladder, H1 2018

Figure 2: Number of Products under Development by Companies, H1 2018

Figure 3: Number of Products by Top 10 Targets, H1 2018

Figure 4: Number of Products by Stage and Top 10 Targets, H1 2018

Figure 5: Number of Products by Top 10 Mechanism of Actions, H1 2018

Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Figure 7: Number of Products by Routes of Administration, H1 2018

Figure 8: Number of Products by Stage and Routes of Administration, H1 2018

Figure 9: Number of Products by Molecule Types, H1 2018

Figure 10: Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Allergan Plc
  • Asahi Kasei Pharma Corp
  • Astellas Pharma Inc
  • Dompe Farmaceutici SpA
  • Dong-A ST Co Ltd
  • FemmePharma Global Healthcare Inc
  • Hanmi Pharmaceuticals Co Ltd
  • Hydra Biosciences Inc
  • Ion Channel Innovations LLC
  • Ipsen SA
  • Juniper Pharmaceuticals Inc
  • Kissei Pharmaceutical Co Ltd
  • Kyorin Pharmaceutical Co Ltd
  • Lipella Pharmaceuticals Inc
  • Medy-Tox Inc
  • Merck & Co Inc
  • Mezzion Pharma Co Ltd
  • Mylan NV
  • Pfizer Inc
  • Recordati SpA
  • Taiho Pharmaceutical Co Ltd
  • Taris Biomedical LLC
  • TheraVida Inc
  • Toray Industries Inc
  • XuanZhu Pharma Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll